In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, 4D Molecular Therapeutics Inc’s stock clocked out at $2.77, down -3.99% from its previous closing price of $2.88. In other words, the price has decreased by -$3.99 from its previous closing price. On the day, 0.56 million shares were traded. FDMT stock price reached its highest trading level at $2.8527 during the session, while it also had its lowest trading level at $2.67.
Ratios:
To gain a deeper understanding of FDMT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.92 and its Current Ratio is at 14.92. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on January 13, 2025, Downgraded its rating to Market Perform and sets its target price to $15 from $40 previously.
On November 21, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 16 ’24 when Bizily Scott sold 500 shares for $16.33 per share. The transaction valued at 8,165 led to the insider holds 6,781 shares of the business.
Bizily Scott sold 500 shares of FDMT for $7,500 on Aug 19 ’24. The Chief Legal Officer now owns 6,781 shares after completing the transaction at $15.00 per share. On Jul 16 ’24, another insider, Bizily Scott, who serves as the Chief Legal Officer of the company, sold 1,750 shares for $27.11 each. As a result, the insider received 47,442 and left with 6,781 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FDMT now has a Market Capitalization of 128257648 and an Enterprise Value of -272013344. For the stock, the TTM Price-to-Sale (P/S) ratio is 3206.50 while its Price-to-Book (P/B) ratio in mrq is 0.25. Its current Enterprise Value per Revenue stands at -7351.712 whereas that against EBITDA is 1.485.
Stock Price History:
The Beta on a monthly basis for FDMT is 2.86, which has changed by -0.9036522 over the last 52 weeks, in comparison to a change of -0.024663687 over the same period for the S&P500. Over the past 52 weeks, FDMT has reached a high of $29.26, while it has fallen to a 52-week low of $2.87. The 50-Day Moving Average of the stock is -37.24%, while the 200-Day Moving Average is calculated to be -72.78%.
Shares Statistics:
It appears that FDMT traded 818.32K shares on average per day over the past three months and 779960 shares per day over the past ten days. A total of 45.79M shares are outstanding, with a floating share count of 39.63M. Insiders hold about 14.40% of the company’s shares, while institutions hold 91.98% stake in the company. Shares short for FDMT as of 1741910400 were 5028368 with a Short Ratio of 6.14, compared to 1739491200 on 6167568. Therefore, it implies a Short% of Shares Outstanding of 5028368 and a Short% of Float of 11.3000005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
